Shares of Nano X Imaging jumped 7.1% to $0.95 after the company announced an exclusive three-year deal handing UK distributor Vertec Scientific the right to sell its AI-powered bone-health software across Britain. The move lands just hours before Nanox is expected to report second-quarter results — a one-two punch of news that raises the stakes for a company whose market cap has shriveled to roughly $74 million and whose stock has lost more than 80% of its value in the past year.
• Britain's Health Watchdog Already Blessed the Product
In November 2025, the UK's National Institute for Health and Care Excellence (NICE) recommended the software among five AI technologies for National Health Service use to help detect spinal fractures. That endorsement matters because NHS adoption is often gated by NICE approval. Vertec, founded in Berkshire in 1979, is one of the UK's leading suppliers of bone-density scanning equipment, serving hospitals and clinics nationwide. In short, Nanox paired a pre-approved product with a partner that already calls on the exact buyers it needs.
• The Revenue Needle May Barely Move — For Now
In Q2 2026, Nanox generated about $1.0 million from AI and software solutions — a small slice of preliminary total quarterly revenue of roughly $4.0 to $4.1 million. One UK reseller deal, even with minimum annual license commitments, is unlikely to transform that figure overnight. But it does prove the company can sign distribution contracts outside the U.S. — a template it could replicate.
• Cash Is the Real Worry Behind the Headlines
Cash and deposits fell to $31.4 million from $60.0 million, and management has raised going-concern and funding concerns. That means the company has flagged doubts about whether it can keep operating without fresh capital. A distribution deal generates licensing fees, not a cash windfall, so investors should watch tonight's earnings call for any update on fundraising plans.
• The Earnings Report Could Overshadow the Deal Itself
Five analysts forecast Q2 earnings per share of -$0.16 on revenue of $5.49 million — a 27% jump from last quarter.
After Q1, the stock cratered 44% following the earnings release. The Vertec deal gives bulls a talking point, but the real verdict arrives when management details burn rate, deal pipeline, and whether the company can survive long enough to turn these partnerships into meaningful income.